Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BeiGene, Ltd. Appoints Jane Huang as Chief Medical Officer, Hematology

09/06/2016 | 04:15pm EST

BeiGene, Ltd. announced the appointment of Jane E. Huang, M.D. as Chief Medical Officer, Hematology. Dr. Huang will lead the global clinical development of BGB-3111, BeiGene’s BTK inhibitor, and the expanding pipeline of other agents expected to enter clinical development in hematological malignancies and disorders. Dr. Eric Hedrick, who served as the Interim Chief Medical Officer, will remain with BeiGene in an advisory role as the company continues to expand its global clinical development capabilities. Prior to joining BeiGene, Dr. Huang was the Vice President and Head of Development at Acerta Pharma, where she oversaw global clinical development of the BTK inhibitor, acalabrutinib. Previously, she served as Group Medical Director at Genentech, where she spent 10 years and played a leading role in drug development programs for several molecules at all stages of development, including venetoclax and obinutuzumab.


© S&P Capital IQ 2016
All news about BEIGENE, LTD.
11/24BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatme..
AQ
11/24BeiGene to Conduct Price Consultations on Nov. 29 for Planned Shanghai IPO
MT
11/23BeiGene Bags EU Approval for Blood Cancer Drug Brukinsa
MT
11/23BeiGene Completes Land Purchase for US Manufacturing, R&D Center
MT
11/23EU Approves BeiGene's Cancer Medicine as Treatment for Waldenström's Macroglobulinemia
MT
11/23BeiGene, Ltd. Closes on Property for New U.S. Manufacturing and Clinical R&D Center
CI
11/23BEIGENE : Launches Proposed Initial Public Offering on the STAR Market in China - Form 8-K
PU
11/23BeiGene's Blood Cancer Treatment Receives European Commission Approval
MT
11/23BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/23BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatme..
BU
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2021 1 209 M - -
Net income 2021 -1 148 M - -
Net cash 2021 3 103 M - -
P/E ratio 2021 -28,0x
Yield 2021 -
Capitalization 32 622 M 32 622 M -
EV / Sales 2021 24,4x
EV / Sales 2022 21,8x
Nbr of Employees 7 600
Free-Float 67,7%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 347,69 $
Average target price 434,18 $
Spread / Average Target 24,9%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Lai Wang Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.34.56%32 622
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678